Pluristem Announces Significant New Finding from Its Phase I/II Muscle Injury Trial and Excellent Safety Profile for PLX-PAD Cells at Twelve Months
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, announced an important new finding from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury after total hip arthroplasty (THA). Data showed that six months after surgery the magnitude of improvement in muscle force of the contralateral (non-operated) gluteal muscle was approximately 40 times larger in patients treated with 150 million PLX-PAD cells than in those who received placebo, and the difference was...
View full press release